{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"73.7","value":"3488"},{"groupId":"OG001","spread":"38.0","value":"5468"},{"groupId":"OG002","spread":"33.4","value":"5597"},{"groupId":"OG003","spread":"63.9","value":"5616"},{"groupId":"OG004","spread":"23.1","value":"7831"},{"groupId":"OG005","spread":"41.5","value":"8078"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"6"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"nab-paclitaxel 120 mg/m\\^2 intravenously (IV) on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the recommended phase 2 dose (RP2D).","id":"OG000","title":"Phase 1: Nab-Paclitaxel 120 mg/m^2"},{"description":"nab-paclitaxel 150 mg/m\\^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.","id":"OG001","title":"Phase 1: Nab-Paclitaxel 150 mg/m^2"},{"description":"nab-paclitaxel 180 mg/m\\^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.","id":"OG002","title":"Phase 1: Nab-Paclitaxel 180 mg/m^2"},{"description":"nab-paclitaxel 210 mg/m\\^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.","id":"OG003","title":"Phase 1: Nab-Paclitaxel 210 mg/m^2"},{"description":"nab-paclitaxel 240 mg/m\\^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.","id":"OG004","title":"Phase 1: Nab-Paclitaxel 240 mg/m^2"},{"description":"nab-paclitaxel 270 mg/m\\^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.","id":"OG005","title":"Phase 1: Nab-Paclitaxel 270 mg/m^2"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic (PK) population: all participannts who received at least one dose of nab-paclitaxel and had evaluable concentration data.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 (Participants ≥ 6 years: 1-2 minutes prior to the end of infusion [EOI], and 15 minutes, 1, 3, 5, 8, 24, 48, and 72 hours after the EOI. Participants <6 years: 1-2 minutes prior to the EOI, and 15 minutes, 3, 5, and 24 hours after the EOI.)","title":"Phase 1: Maximum Observed Concentration of Paclitaxel in Blood Plasma (Cmax)","type":"SECONDARY","unitOfMeasure":"ng/mL"}